BioSpace News Archive

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the first patient has been enrolled in the Company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in near vision, known as VISION-2.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, and Linda Rubinstein, Chief Financial Officer, will participate in the following upcoming investor conferences in November.

Vaccinex, Inc. announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, is scheduled to present virtually at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in virtual one-on-one meetings on Thursday and Friday, November 18th and 19th.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences.

Oyster Point Pharma, Inc., announced it has launched a patient support program called TEAMTyrvaya™ where eligible1 patients can pay as little as $0 for TYRVAYA™ Nasal Spray 0.03 mg.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ET to report its second quarter 2022 financial results and operational highlights.

Lipocine Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis (“NASH”). LPCN 1144

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments for its third quarter ended September 30, 2021.

NeuroBo Pharmaceuticals, Inc. today announced that the Company has appointed Gil Price, M.D. as President and Chief Executive Officer.